STEREOTAXIS INC (OTCMKTS:STXS) Sellers Rose Their Shorts By 0.59% As Of Nov 10, 2018

Stereotaxis, Inc. (OTCMKTS:STXS) Corporate Logo

During Q2 2018 the big money sentiment is 0. That’s change of 2018Q1’s as. 0 investors sold all, 0 reduced holdings as Stereotaxis, Inc. ratio is the same. 0 rose holdings while only 0 funds acquired holdings. Funds hold 13.69 million shares thus 50.00% less from 2018Q1’s 27.38 million shares.
Dafna Cap Management Limited Liability Com reported 4.93% stake. The California-based Everett Harris & Co Ca has invested 0% in Stereotaxis, Inc. (OTCMKTS:STXS).

STEREOTAXIS INC (OTCMKTS:STXS) reported an increase of 0.59% in short interest. FINRA issued in November STXS’s total 137,000 short interest. Previously was reported up change of 0.59% from 136,200 shares. STEREOTAXIS INC (OTCMKTS:STXS) has 89,200 shares average volume. It’ll cost 2 days for STXS to recover its previous position.

Ticker’s shares touched $1.2185 during the last trading session after 4.15% change.Currently Stereotaxis, Inc. is after 0.00% change in last November 10, 2017. STXS has 17,115 shares volume. STXS underperformed the S&P 500 by 15.62%.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally.The firm is valued at $71.91 million. The Company’s products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures.Last it reported negative earnings. The firm also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks worldwide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.